Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant
The coronavirus disease (COVID-19) pandemic continues to spread globally, with new variants emerging. One of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is the B.1.1.7 or U.K. variant. It is still unclear if the developed vaccines can protect against new emerging variants.
Now, researchers at the COVID-19 Genomics United Kingdom Consortium, the AMPHEUS Project, and the Oxford COVID-19 Vaccine Trial Group released the results of their exploratory analysis of a randomized controlled trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine against the SARS-CoV-2 variant of concern 202012/01 or the B.1.1.7 variant.
Published in
Coronavirus | Vaccine centres to be open on all days in April
Updated:
Updated:
Objective is to increase pace and coverage of vaccination
Share Article
AAA
People give their details before getting vaccinated at a COVID-19 government health care centre, in New Delhi, Thursday, April 1, 2021. The third phase of the COVID-19 vaccination drive for 65 lakh people aged above 45 has begun in the national capital from today. | Photo Credit:
PTI
Objective is to increase pace and coverage of vaccination The Centre has decided to operationalise both public and private COVID Vaccination Centres (CVCs) on all days in April, according to a statement from the Health Ministry on Thursday.
Our feline friends are also vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to new research posted to the preprint server bioRxiv. The researchers diagnosed two cats living in France with mild symptomatic COVID-19 illness. The virus was most likely transmitted from their owners.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Quidel Supports New NIH, CDC Public Health Initiative for At-home COVID-19 Testing
April 1, 2021 GMT
SAN DIEGO (BUSINESS WIRE) Mar 31, 2021
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is partnering with the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) on an innovative community health initiative called “Say Yes! COVID Test” in Pitt County, North Carolina, and coming soon to Chattanooga/Hamilton County, Tennessee. Quidel is providing two million QuickVue® At-Home OTC COVID-19 Tests to be distributed to approximately 160,000 residents free of charge across the two communities. The study is designed to determine if access to at-home rapid antigen tests three times a week for one month ca
Can asymptomatic COVID-19 confer long-term immunity?
The coronavirus disease 2019 (COVID-19) is a heterogeneous disease caused by the novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A significant number of SARS-CoV-2 infections, however, occur without any evident symptoms.
In such asymptomatic cases, the role of humoral immunity is unclear. Are antibodies elicited from asymptomatic cases? And, if so, how long do they last?
To address some of these pressing questions, a team of researchers recently compared antibody responses in 405 asymptomatic individuals with 459 symptomatic COVID-19 patients. They found that IgM responses rapidly declined in both groups. However, they found striking differences concerning the strength and persistence of SARS-CoV-2-specific IgG responses. The team has released their results on the